A Phase 3 interventional study of GWP42003-P 20 mg/kg/day Dose and Placebo in Epilepsy and Lennox-Gastaut Syndrome, sponsored by Jazz Pharmaceuticals. Completed at 24 sites in 3 countries. Open to participants aged 2 Years to 55 Years. Per ClinicalTrials.gov, last updated 2022-09-28.
Sponsored by Jazz Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing cannabidiol in Lennox Gastaut Syndrome — 2 open to participants now, 3 under way, none of them phase 3. Cannabidiol · Lennox Gastaut Syndrome.
Among the 13 studies testing cannabidiol in Lennox Gastaut Syndrome, this one is the 3rd largest by enrollment, is one of 3 that started in 2015, is one of 7 in phase 3, and was the 1st registered.
68 studies on the registry are indexed under Lennox Gastaut Syndrome; 13 are open to participants now.
Browse Lennox Gastaut Syndrome studies →2 of the 13 studies testing cannabidiol in Lennox Gastaut Syndrome are open now, in 2 countries. Recruiting first, the newest first:
Elizabeth Donner · Sites in Canada
Ages 2–18
Jazz Pharmaceuticals · Sites in United States
Ages 18+
By country, each count listing its studies:
Cannabidiol: first FDA approval 2018 (EPIDIOLEX), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 4 Lennox Gastaut Syndrome studies recruiting now, none set no upper age limit and 4 stop at 75 or younger; 3 take children under 18; none take healthy volunteers.
This study: 2 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 3 7 · Phase 4 4
First in 2015; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 171 is above the median of 40 across 49 interventional studies indexed under Lennox Gastaut Syndrome.
Median enrollment 40 across the 13 interventional studies. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 13 have an industry lead sponsor. The 7 most frequent:
Jazz Pharmaceuticals is the lead sponsor of 173 studies on the registry; 18 are open to participants now.
Of its 42 completed or terminated interventional studies of FDA-regulated products, 32 (76%) have results posted.
Jazz Pharmaceuticals has 8 studies filed under Lennox Gastaut Syndrome — fewer than ten, so there is no comparison to draw.
1 of the studies testing cannabidiol in Lennox Gastaut Syndrome that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05044819Jazz PharmaceuticalsAssessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution | 2027-08-01 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies testing cannabidiol in Lennox Gastaut Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy of GWP42003-P as adjunctive treatment in reducing the number of drop seizures when compared with placebo, in participants with Lennox-Gastaut Syndrome (LGS).
This study was a 1:1 randomized, double-blind, 14-week comparison of 20 milligram [mg] per kilogram [kg] per day [mg/kg/day] of GWP42003-P versus placebo. The treatment period consisted of a 2-week titration period followed by a 12-week maintenance period. The study determined the efficacy, safety and tolerability of GWP42003-P compared with placebo. The dose was recommended by the Data Safety Monitoring Committee (DSMC) after assessment of safety and pharmacokinetic data from Part A of study GWEP1332. The first participants enrolled into this study after the DSMC reviewed the safety data from Part A of study GWEP1332. Following study completion, all participants were invited to continue to receive GWP42003-P in an open label extension (OLE) study (under a separate protocol).
68 studies on the registry are indexed under Lennox Gastaut Syndrome; 13 are open to participants now.
This study's enrollment of 171 is above the median of 40 across 49 interventional studies indexed under Lennox Gastaut Syndrome.
Browse Lennox Gastaut Syndrome studies →Jazz Pharmaceuticals is the lead sponsor of 173 studies on the registry; 18 are open to participants now.
Of its 42 completed or terminated interventional studies of FDA-regulated products, 32 (76%) have results posted.
Compared within Lennox Gastaut Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Epilepsy. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received GWP42003-P 20 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
Drug: GWP42003-P 20 mg/kg/day Dose
Participants received placebo (0 mg/mL CBD), volume matched to the 20 mg/kg/day dose, administered orally, half in the morning and half in the evening. To maintain the blinded aspect of the study, participants titrated the placebo dose over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
Drug: Placebo
Drug page: Cannabidiol
GWP42003-P was presented as an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
Also known as: Cannabidiol, Epidiolex
Placebo was presented as an oral solution containing 0 mg/mL CBD in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
Percentage Change From Baseline In Drop Seizure Frequency During The Treatment Period
Drop seizures were recorded by the participant or caregiver using an interactive voice response system (IVRS) diary. Drop seizures were defined as the subset of tonic-clonic, tonic or atonic seizures that were reported as drop seizures in the IVRS. Percentage change from baseline was calculated as: (frequency during the treatment period - frequency during baseline/frequency during baseline) \* 100. The frequency during each period was based on 28-day averages and calculated as: (number of seizures in the period/number of reported days in the IVRS period) \*28. Baseline included all available data prior to Day 1 (28-day average). Negative percentages show an improvement from baseline.
Time frame: Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)
Number Of Participants With a ≥50% Reduction From Baseline in Drop Seizure Frequency During The Treatment Period
Drop seizures were recorded by the participant or caregiver using an IVRS diary. Drop seizures included the subset of tonic-clonic, tonic or atonic seizures that were reported as drop seizures in IVRS. Percentage change from baseline was calculated as per the primary outcome measure.
Time frame: Baseline to EOT (Day 99) or ET
Percentage Change From Baseline In Total Seizure Frequency During The Treatment Period
Total seizures included the sum of all seizures (tonic-clonic, tonic, atonic, clonic, myoclonic, countable partial, other partial and absence seizures) recorded by the participant or caregiver using an IVRS diary. Percentage change from baseline was calculated as per the primary outcome measure. Negative percentages show an improvement from baseline.
Time frame: Baseline to EOT (Day 99) or ET
Subject/Caregiver Global Impression Of Change Assessment (S/CGIC)
The S/CGIC was used to assess the participant's overall condition on a 7-point scale, using the markers "very much improved, much improved, slightly improved, no change, slightly worse, much worse, or very much worse" (1 = very much improved; 7 = very much worse). On Day 1 (prior to starting IMP), the caregiver was asked to write a brief description of the participant's overall condition as a memory aid for the S/CGIC questionnaire at subsequent visits. If both a CGIC and SGIC were completed then the CGIC was used; if only a CGIC was completed then the CGIC was used; if only a SGIC was completed then the SGIC was used. Last visit for endpoints assessed at clinic visits was defined as the last scheduled visit (not including the end of taper or safety follow-up visits) at which participant's last evaluation was performed.
Time frame: Baseline to Last Visit (Day 99) or ET
| Milestone | GWP42003-P 20 mg/kg/Day Dose | Placebo |
|---|---|---|
| Started | 86 | 85 |
| Safety analysis set | 86 | 85 |
| Intent to treat (itt) analysis set | 86 | 85 |
| Completed | 72 | 84 |
| Not completed | 14 | 1 |
| Withdrew: Adverse event | 8 | 1 |
| Withdrew: Met withdrawal criteria | 4 | 0 |
| Withdrew: Use of g-tube | 1 | 0 |
| Withdrew: Did not meet eligibility criteria | 1 | 0 |
Drop seizures were recorded by the participant or caregiver using an interactive voice response system (IVRS) diary. Drop seizures were defined as the subset of tonic-clonic, tonic or atonic seizures that were reported as drop seizures in the IVRS. Percentage change from baseline was calculated as: (frequency during the treatment period - frequency during baseline/frequency during baseline) \* 100. The frequency during each period was based on 28-day averages and calculated as: (number of seizures in the period/number of reported days in the IVRS period) \*28. Baseline included all available data prior to Day 1 (28-day average). Negative percentages show an improvement from baseline.
| percentage change | GWP42003-P 20 mg/kg/Day Dose | Placebo |
|---|---|---|
| Percentage Change From Baseline In Drop Seizure Frequency During The Treatment Period | -43.90 (-69.62 to 1.93) | -21.80 (-45.72 to 1.74) |
Drop seizures were recorded by the participant or caregiver using an IVRS diary. Drop seizures included the subset of tonic-clonic, tonic or atonic seizures that were reported as drop seizures in IVRS. Percentage change from baseline was calculated as per the primary outcome measure.
| Participants | GWP42003-P 20 mg/kg/Day Dose | Placebo |
|---|---|---|
| Number Of Participants With a ≥50% Reduction From Baseline in Drop Seizure Frequency During The Treatment Period | 38 | 20 |
Total seizures included the sum of all seizures (tonic-clonic, tonic, atonic, clonic, myoclonic, countable partial, other partial and absence seizures) recorded by the participant or caregiver using an IVRS diary. Percentage change from baseline was calculated as per the primary outcome measure. Negative percentages show an improvement from baseline.
| percentage change | GWP42003-P 20 mg/kg/Day Dose | Placebo |
|---|---|---|
| Percentage Change From Baseline In Total Seizure Frequency During The Treatment Period | -41.24 (-62.85 to -13.00) | -13.70 (-45.00 to 7.27) |
The S/CGIC was used to assess the participant's overall condition on a 7-point scale, using the markers "very much improved, much improved, slightly improved, no change, slightly worse, much worse, or very much worse" (1 = very much improved; 7 = very much worse). On Day 1 (prior to starting IMP), the caregiver was asked to write a brief description of the participant's overall condition as a memory aid for the S/CGIC questionnaire at subsequent visits. If both a CGIC and SGIC were completed then the CGIC was used; if only a CGIC was completed then the CGIC was used; if only a SGIC was completed then the SGIC was used. Last visit for endpoints assessed at clinic visits was defined as the last scheduled visit (not including the end of taper or safety follow-up visits) at which participant's last evaluation was performed.
| Participants | GWP42003-P 20 mg/kg/Day Dose | Placebo |
|---|---|---|
| Very Much Improved | 15 | 5 |
| Much Improved | 14 | 9 |
| Slightly Improved | 20 | 15 |
| No Change | 27 | 43 |
| Slightly Worse | 7 | 9 |
| Much Worse | 1 | 2 |
| Very Much Worse | 0 | 2 |
Collected over Day 1 through Day 137 (Safety Follow-up). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GWP42003-P 20 mg/kg/Day Dose | — | 20/86 (23.3%) | 53/86 (61.6%) |
| Placebo | — | 4/85 (4.7%) | 43/85 (50.6%) |
| Event | GWP42003-P 20 mg/kg/Day Dose | Placebo |
|---|---|---|
| Alanine aminotransferase increasedInvestigations | 4/86 | 0/85 |
| Aspartate aminotransferase increasedInvestigations | 4/86 | 0/85 |
| PneumoniaInfections and infestations | 3/86 | 0/85 |
| Gamma-glutamyltransferase increasedInvestigations | 3/86 | 0/85 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 3/86 | 0/85 |
| DehydrationMetabolism and nutrition disorders | 0/86 | 2/85 |
| Viral infectionInfections and infestations | 2/86 | 0/85 |
| ConvulsionNervous system disorders | 2/86 | 0/85 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 2/86 | 0/85 |
| PyrexiaGeneral disorders | 0/86 | 1/85 |
| Event | GWP42003-P 20 mg/kg/Day Dose | Placebo |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 16/86 | 7/85 |
| VomitingGastrointestinal disorders | 8/86 | 14/85 |
| SomnolenceNervous system disorders | 12/86 | 8/85 |
| PyrexiaGeneral disorders | 11/86 | 7/85 |
| Decreased appetiteMetabolism and nutrition disorders | 11/86 | 2/85 |
| SedationNervous system disorders | 7/86 | 1/85 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 7/86 | 2/85 |
| Upper respiratory tract infectionInfections and infestations | 2/86 | 6/85 |
| RashSkin and subcutaneous tissue disorders | 6/86 | 1/85 |
| ConvulsionNervous system disorders | 3/86 | 5/85 |
| Age, Continuous(years) | GWP42003-P 20 mg/kg/Day Dose | Placebo | Total |
|---|---|---|---|
| Mean | 15.478 ± 8.685 | 15.284 ± 9.7945 | 15.381 ± 9.2264 |
| Sex: Female, Male(Participants) | GWP42003-P 20 mg/kg/Day Dose | Placebo | Total |
|---|---|---|---|
| Female | 41 | 42 | 83 |
| Male | 45 | 43 | 88 |
Ran from Apr 2015 to primary completion in Mar 2016, 10 months.
Results were first posted in Jul 2018, 2 years 4 months after primary completion. A results delay was requested in Feb 2017.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cannabidiol